Melanie Davies is Professor of Diabetes Medicine at the University of Leicester and an Honorary Consultant Diabetologist at the University Hospitals of Leicester NHS Trust, Leicester, UK. She is based in the Diabetes Research Centre, University of Leicester and is also the Co-Director of the Leicester Diabetes Centre, which has over 160 research staff, at the University Hospitals of Leicester NHS Trust. She trained at Sheffield and then completed her training at Cambridge, Ipswich and Leicester.

Professor Davies’ research interests include the causes, screening, prevention, self-management and treatment of type 2 diabetes mellitus. She is a National Institute for Health Research Senior Investigator Emeritus and Director of the NIHR Leicester Biomedical Research Centre. Professor Davies is the Principal Investigator on a number of large global studies in the field of diabetes, obesity, physical activity, sedentary behaviour and cardiovascular disease and has served as an expert for the UK’s National Institute for Health and Care Excellence (NICE) on a number of guideline groups. She was co-chair of EASD/ADA’s recent Consensus Report on Type 2 Diabetes Mellitus Management.

Professor Davies has published over 800 original articles in national and international peer-reviewed journals, such as the LancetNEJM and BMJ and has over £90M of peer review grant funding. She has authored more than 510 published abstracts and 10 book chapters and is Co-editor of the diabetes section in the 2011 Oxford Textbook of Endocrinology and Diabetes. She was awarded the CBE (Commander of the Most Excellent Order of the British Empire) in the 2016 New Year’s Honour’s List for services to diabetes research and awarded Fellowship of the Academy of Medical Sciences in 2018. 

Duality of Interest: Professor Melanie Davies has received research support /grants in support of investigator and investigator initiated trials from Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, AstraZeneca Janssen and Eli Lilly and speaker’s honorarium / fees from Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, Astra Zeneca, Napp Pharmaceuticals, Novartis and Amgen. She has also received board member / advisor panel fees from Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, AstraZeneca, Pfizer, ShouTi Pharma, Lexicon and Medtronic together with consultancy fees from Boehringer Ingelheim, Novo Nordisk, Lilly and Sanofi.

Date: Autumn 2023